Great Lakes Advisors LLC Takes Position in Enovis Corporation $ENOV

Great Lakes Advisors LLC purchased a new position in Enovis Corporation (NYSE:ENOV) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 76,726 shares of the company’s stock, valued at approximately $1,588,000. Great Lakes Advisors LLC owned approximately 0.13% of Enovis as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of the stock. Rubric Capital Management LP bought a new stake in shares of Enovis in the 3rd quarter worth $83,435,000. Paradigm Capital Management Inc. NY boosted its holdings in Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after buying an additional 732,917 shares during the period. AQR Capital Management LLC grew its position in shares of Enovis by 682.6% in the second quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after purchasing an additional 434,646 shares in the last quarter. Front Street Capital Management Inc. grew its holdings in Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after buying an additional 384,124 shares in the last quarter. Finally, Quantinno Capital Management LP increased its position in shares of Enovis by 130.8% during the first quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock valued at $13,752,000 after buying an additional 342,556 shares during the period. Institutional investors own 98.45% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on ENOV. BTIG Research increased their target price on shares of Enovis from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Evercore set a $32.00 price target on Enovis in a research report on Monday, July 6th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Enovis in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $41.29.

Enovis Trading Up 0.2%

NYSE ENOV opened at $26.22 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. The stock’s 50-day simple moving average is $25.22 and its two-hundred day simple moving average is $24.15. Enovis Corporation has a twelve month low of $19.14 and a twelve month high of $34.28. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -1.36 and a beta of 1.34.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. The firm had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The company’s revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts forecast that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert bought 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have acquired 4,200 shares of company stock worth $92,084. 2.90% of the stock is currently owned by company insiders.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.